Experience With NovoPen®, an Injection Device using Cartridged Insulin, for Diabetic Patients

Abstract

An insulin injection device, NovoPen®, incorporating cartridged U100 Human Actrapid insulin was used in a group of 31 insulin-dependent diabetic patients aged 31.4±11.2 years (mean±S.D.; range 16.5–57.0) to assess its acceptance and suitability in a regimen involving an injection before each of their three main meals plus an evening injection of Human Monotard® insulin from a conventional syringe. Twenty-seven patients completed 48 weeks of NovoPen® therapy and preferred to continue with the multiple injection regimen in the long term. The device was well accepted and may make multiple injection regimens more feasible.